Financial Performance - The company achieved operating revenue of ¥258,700,268.97, an increase of 23.88% compared to the previous year[3] - Net profit attributable to shareholders reached ¥56,442,153.33, up 69.39% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥51,415,806.81, reflecting a 67.82% increase from the previous year[4] - Basic earnings per share increased to ¥1.88, a rise of 69.37% compared to the same period last year[4] Assets and Equity - Total assets at the end of the reporting period were ¥380,716,880.35, a 10.67% increase from the beginning of the period[4] - Shareholders' equity attributable to the company was ¥309,025,777.03, growing by 18.13% from the start of the period[4] - The net asset value per share attributable to shareholders was estimated at ¥10.29, an increase of 18.14% from the beginning of the period[4] Sales Performance - The sales revenue of antiviral, antioxidant, and antithrombotic drug intermediates increased by approximately 58% during the reporting period[5] Cautionary Note - The company emphasizes that the financial data is preliminary and has not been audited, urging investors to be cautious[6] Share Capital - The company maintained a consistent share capital of ¥30,037,500.00 throughout the reporting period[4]
峆一药业(430478) - 2022 Q4 - 年度业绩